Informējam, ka Sistēma pielāgota darbam ar interneta pārlūkprogrammu Internet Explorer (8. un jaunākām versijām) un Mozilla Firefox (3.6 un jaunākām versijām).
Izmantojot citu interneta pārlūkprogrammu, brīdinām, ka Sistēmas funkcionalitāte var tikt traucēta.
This document specifies definitions and general requirements for developing and reporting a certificate of analysis (CoA) and a certificate of origin (CoO) for ancillary materials (AMs) used in manufacturing of cell and gene therapy products (excluding single use components).
This document includes minimum requirements for ancillary material CoA and CoO reporting and management.
This document is applicable to ancillary materials used in cell and gene therapy product manufacturing (e.g., cell culture media and its components, cytokines used in cell expansion, reagents used in vector manufacturing, etc.).
This document is applicable to AM suppliers and AM users, i.e., manufacturers of cell and gene products.
NOTE International, regional or national regulations or requirements can also apply to specific topics covered in this document.
Reģistrācijas numurs (WIID)
92505
Darbības sfēra
This document specifies definitions and general requirements for developing and reporting a certificate of analysis (CoA) and a certificate of origin (CoO) for ancillary materials (AMs) used in manufacturing of cell and gene therapy products (excluding single use components).
This document includes minimum requirements for ancillary material CoA and CoO reporting and management.
This document is applicable to ancillary materials used in cell and gene therapy product manufacturing (e.g., cell culture media and its components, cytokines used in cell expansion, reagents used in vector manufacturing, etc.).
This document is applicable to AM suppliers and AM users, i.e., manufacturers of cell and gene products.
NOTE International, regional or national regulations or requirements can also apply to specific topics covered in this document.
